Orthopaedic specialists join forces to widen access to novel knee osteoarthritis treatment for patients across Europe
Contura Orthopaedics Ltd has entered into an exciting new partnership with leading global expansion orthpaedic specialists Ortho Consulting Group (OCG) to extend the distribution of its novel knee osteoarthritis treatment Arthrosamid® to the European market. The agreement (formally signed on January 21st, 2022) will facilitate the recruitment and management of a network of distributors in order to engage leading orthopaedic specialists to introduce Arthrosamid®.
Arthrosamid® is a polyacrylamide hydrogel developed by Contura as a long-lasting intra-articular injection approved in Europe to provide sustained pain relief from knee osteoarthritis (OA). A number of clinical studies have been completed into Arthrosamid® with further trials ongoing. Published data has already shown that over 70% of patients had a positive experience of treatment, exceeding a minimal clinically important difference, with a reduction in pain, stiffness and physical mobility at 6 months with pain and physical function maintained beyond one year.1
Rakesh Tailor CEO Contura International Ltd comments:
“We’re absolutely delighted to partner with Ortho Consulting Group on the European expansion of Arthrosamid®.
“The discomfort caused by knee osteoarthritis (OA) can significantly impact a patient’s quality of life, making everyday activities hugely challenging. For patients not suitable for surgery, or deemed too young for knee replacement surgery, Arthrosamid® represents a game changing option, a safe non-degrading hydrogel in a single injection providing long-acting and sustained pain relief.
“Partnering with OCG who are uniquely positioned to support us, will enable Contura Orthopaedics to accelerate access to Arthrosamid® in Europe, helping many more patients find relief from the pain of knee OA, marking the start of the ambition to make Arthrosamid® available to all patients all around the world.”
Arthrosamid® becomes embedded in the synovial membrane, providing increased cushioning and bringing both pain relief and improved mobility to patients suffering with knee osteoarthritis. The development of Arthrosamid® followed impressive clinical data with Arthramid® Vet, a related product of the company, in the treatment of lameness in horses.
Ortho Consulting Group Director Gavin Crowther adds:
“We’re extremely pleased to formally announce our partnership with Contura Orthopaedics, and to be working alongside their talented team to improve outcomes for patients and clinicians. “With our proven track record, global mindset and customer-focused approach we’re ideally placed to help Contura Orthopaedics fulfil their vision to provide osteoarthritis sufferers with sustained pain relief.
Arthrosamid® is a revolutionary and innovative treatment, and our experienced and dedicated team are excited to build and strengthen European sales channels that will deliver continued growth. We look forward to providing a streamlined and effective solution and to continuing this partnership moving forward.”
Notes to editors:
Contura is headquartered in London and has its manufacturing facility in Copenhagen, Denmark. It develops and manufactures innovative medical products in the fields of women’s health, orthopaedics and animal health using its unique, patented hydrogel technology. Its hydrogel-based products are non-particulate and biocompatible, allowing for its non-absorbable, non-migratory and highly durable properties. For more information, visit contura.com.
About Ortho Consulting Group:
Ortho Consulting Group helps companies within the orthopaedic, spine and medical device industry build and strengthen their global sales channels. We solve the real issues that affect SMEs and start-ups, identifying and managing distributors, building executive teams, providing venture capital and M&A insight. Our clients rely on us because we are committed to developing long-term relationships, immersing ourselves fully in each project, thinking and acting as business partners. Learn more at orthocg.com
1. Bliddal H, Overgaard A, Hartkopp A, Beier J, Conaghan PG, et al. (2021) Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results of a 52 Week Prospective Study. Osteoarthritis and CartilageVol. 29 S278: 2021.